ABT-267: Phase III started

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA, Watertown, Mass.) disclosed in its 4Q13 earnings that partner AbbVie began the placebo-controlled, Japanese Phase III GIFT-I trial to evaluate ABT-450 plus ritonavir and AbbVie's ABT-267 for 12 weeks in about 312 treatment-naïve and treatment-experienced patients with chronic HCV genotype1b infection. The trial comprises a double-blind portion in non-cirrhotic patients and an open-label portion in patients with compensated cirrhosis. ...